Agomelatine: Fulminant liver failure in a patient with fatty liver;Agomelatina: Fallo hepático fulminante en paciente con hígado graso

Gastroenterologia y Hepatologia

Volumn 37, Issue 2, 2014, Pages 92-94

  Gruz, Fernando ^a   Raffa, Sebastián ^a   Santucci, Claudia ^b   Papale, Rosa Maria ^b   Videla, María Grazia ^a   Fernández, María Gimena ^a   Yantorno, Silvina ^a   Descalzi, Valeria I ^a  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN FAVALORO   (Argentina)

^b ANMAT   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

AGOMELATINE; ACETAMIDE DERIVATIVE; ANTIDEPRESSANT AGENT;

CASE REPORT; FATTY LIVER; FULMINANT HEPATIC FAILURE; HUMAN; LETTER; AGED; COMPLICATION; CONTRAINDICATIONS; DEPRESSIVE DISORDER, MAJOR; DRUG INACTIVATION; DRUG-INDUCED LIVER INJURY; EPIDEMIOLOGY; FEMALE; HEPATIC ENCEPHALOPATHY; LIVER; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; METABOLIC SYNDROME X; METABOLISM; NONALCOHOLIC FATTY LIVER;

ACETAMIDES; AGED; ANTIDEPRESSIVE AGENTS; CAUSALITY; DEPRESSIVE DISORDER, MAJOR; DRUG-INDUCED LIVER INJURY; FEMALE; HEPATIC ENCEPHALOPATHY; HUMANS; INACTIVATION, METABOLIC; LIVER; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; METABOLIC SYNDROME X; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84893757679     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1016/j.gastrohep.2013.04.008     Document Type: Letter

References (23)

1. O'Grady J.G., Alexander J.G., Hayllar K.M., Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989, 97:439-445.
2. Bernuau J., Samue D., Durand F., Saliba F., Bourliére M., Adam R., et al. Criteria for emergency liver transplantation in patients with acute viral hepatitis and factor V (FV) below 50% of normal: a prospective study [abstract]. Hepatology 1991, 14:49.
3. Danan G., Benichou C. Causality assessment of adversee reactions to drugs-i. a novel method based on the consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993, 46:1323-1330.
4. Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, et al. Prevalence of mental disorders in Europe: results from the European Study of the Epidemmiology of Mental Disorders (ESEMeD) Project. Acta Psychiatr Scand (Suppl). 2004;420:21-7.
5. Hardeveld F, Spijker J, De Graaf R, Hendrinks SM, Lincht CM, Nolen WA, et al. Recurrence of major depressive disorder across different treatment settings: results from the NESDA study. J Affect Dis. 2013;147:225-31.
6. Sansone R., Sansone L. Agomelatine: a novel antidepressant. Innov Clin Neurosci 2011, 8:10-14.
7. Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: ramdomized, double-blind comparison with venlafaxine.
8. Loo H., Hale A., D'haenen H. Determination of the dose of agomelatine, a melatonnergic agonist and selective 5-HT2c antagonist in the treatment of major depressive disorder: a placebo-controllled dose range study. Int Clin Psychopharmacol 2002, 17:239-247.
9. Goodwin G.M., Emsley R., Rembry S., Rouillon F. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2009, 70:1128-1137.
10. Sapetti A. Agomelatine an antidepressant without deterioration os sexual response. J Sex Marital Ther 2012, 38:190-197.
11. Servier Laboratories.Valdoxan [consultado 3 May 2011]. Disponible en: . http://www.valdoxan.com/index.php/valdoxan-package-leaflet-information-for-the-user/.
12. Chalasani N., Fontana R.J., Bonkovsky H.L., Watkins P.B., Davern T., Serrano J., et al. Causes, clinical features and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008, 135:1924-1934.
13. Daly A.K., Donaldson P.T., Bhatnagar P., Shen Y., Pe'er I., Floratos A., et al. HLA-B*5701 Genotype is a major determinant of drug-induced liver injury due to flucoxicilina. Nat Genet 2009, 41:816-819.
14. Donaldson P.T., Daly A.K., Henderson J., Graham J., Pirmohamed M., Bernal W., et al. Human leukocite antigen class II genotype in suceptibility and resistence to co-amoxiclav-induced liver injury. J Hepatol 2010, 53:1049-1053.
15. Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, García Ruiz E, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish Registry over a 10-year period. Gastroenterology. 2005;129:512-21.
16. Ostapowicz G., Fontana R.J., Schiodt F.B., Larson A., Davern T.J., Han S.H., et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United Status. Ann Intern Med 2002, 137:947-954.
17. Fontana R.J. Approaches to the study of drug-induced liver injury. Clin Pharmacol Ther 2010, 88:416-419.
18. Benichou C., Danan G., Flahault A. Causality assessment of adversee reactions to drugs-II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993, 1331-1336.
19. Mofrad P., Contos M.J., Haque M., Sargeant C., Fisher R.A., Luketic V.A., et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003, 37:1286-1292.
20. Anty R., Lemoine M. Liver fibrogenesis and metabolic factors. Clin Res Hepathol Gastroenterol 2011, 35(Suppl 1):S10-S20.
21. Chalasani N., Younossi Z., Lavine J.E., Diehl A.M., Brunt E.M., Cusi K. The Diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012, 55:2005-2023.
22. Tarantino G., Conca P., Basile V., Gentile A., Capone D., Policcheti G., et al. A prospective study of acute drug-induced liver injury in patietns suffering from non-alcoholic fatty liver disease. Hepatol Res 2007, 37:410-415.
23. Buechler C., Weiss T.S. Does hepatic steatosis affect drug metabolizing enzymes in the liverα. Curr Drug Metabol 2011, 12:24-34.